Augmentin XR's approval under CNPV addresses antibiotic shortages and strengthens U.S. manufacturing, enhancing national security. The CNPV program expedites drug reviews, reducing the timeline from ...
The FDA has approved Augmentin XR, an oral antibacterial, under its Commissioner’s National Priority Voucher pilot program, marking the first approval granted through the expedited review pathway. The ...
The FDA's priority review for Opdivo with AVD targets first-line treatment for stage 3 or 4 cHL in patients aged 12 and older. The phase 3 SWOG S1826 study supports the review, focusing on progression ...
Less than two weeks into his new role as Auburn's head football coach, Alex Golesh has a tremendous task ahead of him. AUBURN, Ala.-- A little over ten days into his tenure on the plains, new Auburn ...
ROCHESTER, N.Y. — The Advance 2 Apprenticeship pre-apprenticeship program celebrated its first-ever graduating class Friday at the Finger Lakes Workforce Development Center. Fourteen people graduated ...
MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...
One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who ...
BOSTON, MA AND SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Access Advance LLC and Via Licensing Alliance announced today Access Advance's acquisition of Via's HEVC/VVC program, a move ...
The MarketWatch News Department was not involved in the creation of this content. TORONTO, ON / ACCESS Newswire / December 18, 2025 / Forum Asset Management ("Forum") today announced the final close ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback